United Therapeutics (UTHR) Q3 2024 earnings summary

Executive summary

• Achieved record Q3 2024 revenue of $749 million, up 23% year-over-year, marking the sixth consecutive record quarter and 16th consecutive quarter of year-over-year growth, driven by strong Tyvaso (DPI and nebulized), Orenitram, and Unituxin sales.

• Net income for Q3 2024 was $309.1 million, up 16% from the prior year, with diluted EPS rising to $6.39.

• Innovation pipeline advancing, with key clinical data and regulatory milestones expected over the next 36 months, including TETON studies for Tyvaso in IPF, ralinepag in PAH, and miroliverELAP phase 1 study underway.

• Strong cash position with $4.6 billion in cash, cash equivalents, and marketable investments as of September 30, 2024.

• Completed $1 billion accelerated share repurchase in Q3, reducing outstanding shares by about 3.5 million (~7%).

Financial highlights

• Q3 2024 revenue was $749 million, up 23% year-over-year, with Tyvaso revenue at $434 million (up 33%), Orenitram at $113 million (up 23%), and Unituxin at $61 million (up 19%).

• Remodulin revenue declined 2% to $128 million, with U.S. Remodulin up 3% year-over-year.

• Net income for Q3 2024 was $309.1 million, with operating income at $405.8 million and gross margin at 89%.

• Trailing twelve-month operating cash flow reached $1.1 billion.

• Cash and marketable investments totaled $4.61 billion at quarter end.

Outlook and guidance

• Confident in sustaining double-digit revenue growth, targeting a $4 billion run rate in 2025 and continued growth beyond.

• Anticipates steady stream of clinical data and regulatory actions through 2026, including TETON, ADVANCE OUTCOMES, and miroliverELAP studies.

• Human clinical studies for xenotransplantation expected to commence in 2025, with UKidney IND filing expected soon.

• Near-term growth driven by Tyvaso DPI and increased PH-ILD patient prescriptions.

• Approximately $600 million in capital expenditures budgeted through 2026, mainly for Tyvaso DPI manufacturing.